| Literature DB >> 29981742 |
Cristina Beltrami1, Kate Simpson2, Mark Jesky3, Alexa Wonnacott1, Christopher Carrington1, Peter Holmans4, Lucy Newbury2, Robert Jenkins1, Thomas Ashdown1, Colin Dayan5, Simon Satchell6, Peter Corish7, Paul Cockwell3, Donald Fraser2, Timothy Bowen8.
Abstract
Effective diabetic kidney disease (DKD) biomarkers remain elusive, and urinary miRNAs represent a potential source of novel noninvasive disease sentinels. We profiled 754 miRNAs in pooled urine samples from DKD patients (n = 20), detecting significantly increased miR-126, miR-155, and miR-29b compared with controls (n = 20). These results were confirmed in an independent cohort of 89 DKD patients, 62 diabetic patients without DKD, and 41 controls: miR-126 (2.8-fold increase; P < 0.0001), miR-155 (1.8-fold increase; P < 0.001), and miR-29b (4.6-fold increase; P = 0.024). Combined receiver operating characteristic curve analysis resulted in an area under the curve of 0.8. A relative quantification threshold equivalent to 80% sensitivity for each miRNA gave a positive signal for 48% of DKD patients compared with 3.6% of diabetic patients without DKD. Laser-capture microdissection of renal biopsy specimens, followed by quantitative RT-PCR, detected miR-155 in glomeruli and proximal and distal tubules, whereas miR-126 and miR-29b were most abundant in glomerular extracts. Subsequent experiments showed miR-126 and miR-29b enrichment in glomerular endothelial cells (GEnCs) compared with podocytes, proximal tubular epithelial cells, and fibroblasts. Significantly increased miR-126 and miR-29b were detected in GEnC conditioned medium in response to tumor necrosis factor-α and transforming growth factor-β1, respectively. Our data reveal an altered urinary miRNA profile associated with DKD and link these variations to miRNA release from GEnCs.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29981742 DOI: 10.1016/j.ajpath.2018.06.006
Source DB: PubMed Journal: Am J Pathol ISSN: 0002-9440 Impact factor: 4.307